Csrwin, I don’t want to harp on but the fda went for the beagle issue, pre phase1...the TGA had phase 1 data to draw on, safety fine, and would’ve approved safety on this and straight into a phase 2...this was were the issue was.
They chose the fda cluster route.
If you reckon current management is doing a great job with the stock at 2cents for a mkt cap $22m, great.... I think it is a joke and the board has to act
Ann: Actinogen presents latest Xanamem data at AD Conference, page-45
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
